BioMarin Pharmaceutical (NASDAQ:BMRN)

Credit Suisse Outlines Top Biotech M&A Targets and Catalyst Stocks for 2018

Get ready for more mergers and acquisitions in biotech and in emerging pharmaceuticals in 2018. This theme is believed by many investors, and now Credit Suisse is touting that tax ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Abercrombie, Arch Coal, Baker Hughes, BioMarin, Gilead, Hasbro, Snap and More

Stocks were indicated to open higher on Thursday. The major stock indexes remain close to all-time highs and the trend that has prevailed for more than five years is that investors ...
Read Full Story »

Top Stocks to Look For on July’s FDA Calendar

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Conoco, Goodyear, Humana, Lululemon, Range Resources and Many More

Stocks were directionless on Thursday with no major news moving the markets one way or the other. Investors proved once again this week that they want to buy any real ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Best Buy, Caterpillar, Nokia, UnitedHealth, Wal-Mart and Many More

Stocks were indicated higher on Tuesday, and the Dow is now up over 20,000 again. Even though the bull market is nearing eight years old, investors keep finding new reasons to ...
Read Full Story »

4 Top Biotech Stocks With Big Upcoming Catalysts

In the world of biotech investing, there are some surefire ways for stocks to move. Pipeline announcements, clinical data and regulatory approval all can move the needle as catalysts for ...
Read Full Story »
Jon's friends

Why Credit Suisse Sees 25% Upside at BioMarin

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has more or less missed out on the Trump rally that we have seen over the past couple of months. However it might not be ...
Read Full Story »
automatic inspection machine

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

Needless to say, the past two years have been rough on biotech. So rough in fact, that a basket of the largest capitalization stocks now trade with a price-to-earnings growth ...
Read Full Story »
choose happiness

RBC Likes Large Cap Biotech Leaders for 2017

After a very poor 2016 for the biotechs, some on Wall Street are beginning to think that the light at the end of the tunnel may not be another train ...
Read Full Story »
buy sell stocks

Top Analyst Upgrades and Downgrades: AK Steel, Celgene, Darden, Delphi Automotive, Johnson & Johnson, US Steel and More

Monday brought a much needed sell-off after two and half weeks of almost constant rallying, but the sell-off was minimal. Tuesday's opening indication on the S&P 500 and Dow is ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: GoPro, Randgold, Teva Pharma, Time Warner, Waste Management and More

Stocks were indicated handily higher, with the Dow up over 200 points and the S&P 500 up 29 points, after the FBI announced new information concerning the Clinton email review. ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

Stocks were indicated higher on Thursday after the Brexit theme has now switched to a softer Brexit path. This is also the first day of serious gains this week. Investors ...
Read Full Story »
biotech word cloud

Top Health Care Earnings Coming Next Week

Earnings season is now in full swing, and we have put together a preview of some of the world’s largest players in the health care sector. This current quarter ahead ...
Read Full Story »
bigger fish

3 Biotech Stocks Could Be the Next Big Takeover Targets

Just as the biotech segment was starting to regain lost ground, and was fast approaching 2016 highs, yet another speed bump was hit. The EpiPen controversy, and the resulting commentary again ...
Read Full Story »

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

The Nasdaq Biotechnology Index has underperformed the broader market for some time. This year the index is still down about 13%, versus the 6% rise for the S&P 500. We ...
Read Full Story »